StemCell Institute Past Earnings Performance
Past criteria checks 4/6
StemCell Institute has been growing earnings at an average annual rate of 24.8%, while the Healthcare industry saw earnings growing at 6.4% annually. Revenues have been growing at an average rate of 16.4% per year. StemCell Institute's return on equity is 14.7%, and it has net margins of 16%.
Key information
24.8%
Earnings growth rate
-2.2%
EPS growth rate
| Healthcare Industry Growth | 7.9% |
| Revenue growth rate | 16.4% |
| Return on equity | 14.7% |
| Net Margin | 16.0% |
| Last Earnings Update | 30 Sep 2024 |
Revenue & Expenses Breakdown
How StemCell Institute makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2,641 | 422 | 1,200 | 0 |
| 30 Jun 24 | 2,582 | 413 | 1,176 | 0 |
| 31 Mar 24 | 2,481 | 310 | 1,143 | 0 |
| 31 Dec 23 | 2,396 | 280 | 1,136 | 0 |
| 30 Sep 23 | 2,268 | 247 | 1,101 | 0 |
| 30 Jun 23 | 2,176 | 223 | 1,071 | 0 |
| 31 Mar 23 | 2,091 | 198 | 1,026 | 0 |
| 31 Dec 22 | 2,044 | 208 | 970 | 0 |
| 30 Sep 22 | 1,952 | 183 | 939 | 0 |
| 30 Jun 22 | 1,849 | 160 | 904 | 0 |
| 31 Mar 22 | 1,781 | 133 | 875 | 0 |
| 31 Dec 21 | 1,661 | 99 | 874 | 0 |
| 31 Mar 21 | 1,409 | 62 | 830 | 0 |
| 31 Dec 20 | 1,470 | 123 | 812 | 0 |
| 31 Mar 20 | 1,676 | 277 | 750 | 0 |
| 31 Mar 19 | 1,149 | 142 | 544 | 0 |
| 31 Mar 18 | 861 | 69 | 468 | 0 |
Quality Earnings: 7096 has a large one-off gain of ¥136.0M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: 7096's current net profit margins (16%) are higher than last year (10.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 7096's earnings have grown significantly by 24.8% per year over the past 5 years.
Accelerating Growth: 7096's earnings growth over the past year (70.9%) exceeds its 5-year average (24.8% per year).
Earnings vs Industry: 7096 earnings growth over the past year (70.9%) exceeded the Healthcare industry 10.6%.
Return on Equity
High ROE: 7096's Return on Equity (14.7%) is considered low.